. What one ex-FDA adviser called ‘probably the worst drug approval decision in recent US history’ for an Alzheimer’s treatment « JO LEE MAGAZINE

CNN- Dr. Aaron Kesselheim had been on an advisory committee for the US Food and Drug Administration for a half-dozen years, but he had never been to a meeting like this one.

The public meeting, conducted as an all-day video call on November 6, 2020, concerned the application for aducanumab, a drug that would be marketed under the name Aduhelm by the company Biogen, which is based in Cambridge, Massachusetts.

Aduhelm, if effective, would address one of the most pressing needs in modern medicine: to slow the symptoms of Alzheimer’s disease.

To Read More





Comments are closed.

 

 


hey